# US 2013/0251733 A1 · Anti-cxcr3 antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0251733 A1
- Document ID: US20130251733A1
- Status: Published application
- Kind: A1
- Application number: 13/745,377
- Filed: 2013-01-18
- Published: 2013-09-26
- Earliest claimed: 2012-01-20
- Assignees: Genzyme Corporation
- Inventors: Michele Youd; Jennifer Tedstone; Tracey Lodie; Karen B. Carter; Timothy D. Connors; Jason Robert Pinckney; Elizabeth Masterjohn; Ruiyin Chu
- Web page: https://patentgrep.com/patent/US20130251733A1

## CPC

- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides anti-CXCR3 antibodies and methods of using the antibodies to diagnose and/or treat CXCR3-associated disorders such as diabetes mellitus type I (T1D), particularly new-onset T1D. In certain embodiments, disclosed herein are CXCR3 neutralizing antibodies.

## Claims

### Claim 1

An antibody or antigen binding fragment capable of binding to CXCR3, wherein the antibody or fragment comprises a heavy chain variable region (VH) and a light chain variable region (VL), and wherein:
a) the heavy chain variable region comprises three complementarity determining regions (CDRs) that are at least about 95% identical to the three CDRs from any one of SEQ ID NO: 2, 4, 6, and 8; and/or the light chain variable region comprises three CDRs that are at least about 95% identical to the three CDRs from any one of SEQ ID NO: 3, 5, 7, and 9,
b) the heavy chain variable region comprises three CDRs that are at least about 95% identical to the three CDRs from any one of SEQ ID NO: 10, 12, 14, and 16; and/or the light chain variable region comprises three CDRs that are at least about 95% identical to the three CDRs from any one of SEQ ID NO: 11, 13, 15, and 17,
c) the heavy chain variable region comprises three CDRs that are at least about 95% identical to the three CDRs from any one of SEQ ID NO: 18, 20, 22, 24, and 26-33; and/or the light chain variable region comprises three CDRs that are at least about 95% identical to the three CDRs from any one of SEQ ID NO: 19, 21, 23, 25, and 34-37,
d) the heavy chain variable region comprises three CDRs that are at least about 95% identical to the three CDRs from any one of SEQ. ID NO: 38, 40, 42, 44, 46-48, and 63-66; and/or the light chain variable region comprises three CDRs that are at least about 95% identical to the three CDRs from any one of SEQ ID NO: 39, 41, 43, 45, 49-54, and 67-70, or
e) the heavy chain variable region comprises three CDRs that are at least about 95% identical to the three CDRs from any one of SEQ ID NO: 55, 57, 59, and 61; and/or the light chain variable region comprises three CDRs that are at least about 95% identical to the three CDRs from any one of SEQ ID NO: 56, 58, 60, and 62.

### Claim 2 (depends on 1)

The antibody or fragment of claim 1; wherein the antibody or fragment is chimeric, CDR grafted, mutated, mutated to remove one or more deamidation site, human, humanized, humanized and back-mutated, synthetic, or recombinant.

### Claim 3 (depends on 1)

The antibody or fragment of claim 1, wherein the antibody or fragment is a Fab, Fab′, a F(ab′)2, an Fv, a single-chain Fv (scFv), a diabody (Fd), a linear antibody, a nanobody (VHH), a bi-specific antibody, or a multi-specific antibody.

### Claim 4 (depends on 1)

The antibody or fragment of claim 1, wherein the antibody or fragment is capable of binding to a peptide selected from
a) a peptide comprising residues 1-58 of SEQ ID NO:1;
b) a peptide comprising residues 1-16 of SEQ ID NO:1; and/or
c) a peptide comprising residues 1-37 of SEQ ID NO:1.

### Claim 5 (depends on 1)

The antibody or fragment of claim 1, wherein the antibody or fragment is capable of binding to a peptide selected from
a) a peptide comprising the amino acid sequence SDHQVLNDAE (SEQ ID NO: 71);
b) a peptide comprising the amino acid sequence SDHQVLND (SEQ ID NO: 72):
c) a peptide comprising the amino acid sequence DHQVLND (SEQ ID NO: 73);
d) a peptide comprising the amino acid sequence VLNDAE (SEQ ID NO: 74);
e) a peptide comprising the amino acid sequence VLND (SEQ ID NO: 75);
f) a peptide comprising the amino acid sequence XDXXVXNDXX (SEQ ID NO: 76);
g) a peptide comprising the amino acid sequence XDXXVXND (SEQ ID NO: 77);
h) a peptide comprising the amino acid sequence DXXVXND (SEQ ID NO: 78);
i) a peptide comprising the amino acid sequence VXNDXX (SEQ ID NO: 79);
and/or
j) a peptide comprising the amino acid sequence VXND (SEQ ID NO: 80),
wherein X indicates any amino acid.

### Claim 6 (depends on 1)

The antibody or fragment of claim 1, wherein:
a) the heavy chain variable region comprises a sequence at least about 90%
identical to any one of SEQ ID NO: 2, 4, 6, and 8;
b) the heavy chain variable region comprises a sequence at least about 90% identical to any one of SEQ ID NO: 10, 12, 14, and 16;
c) the heavy chain variable region comprises a sequence at least about 90% identical to any one of SEQ ID NO: 18, 20, 22, 24, and 26-33;
d) the heavy chain variable region comprises a sequence at least about 90% identical to any one of SEQ ID NO: 38, 40, 42, 44, 46-48, and 63-66; or
e) the heavy chain variable region comprises a sequence at least about 90% identical to any one of SEQ ID NO: 55, 57, 59, and 61.

### Claim 7 (depends on 1)

The antibody or fragment of claim 1, wherein:
a) the light chain variable region comprises a sequence at least about 90% identical to any one of SEQ ID NO: 3, 5, 7, and 9,
b) the light chain variable region comprises a sequence at least about 90% identical to any one of SEQ ID NO: 11, 13, 15, and 17,
c) the light chain variable region comprises a sequence at least about 90% identical to any one of SEQ ID NO: 19, 21, 23, 25, and 34-37,
d) the light chain variable region comprises a sequence at least about 90% identical to any one of SEQ ID NO: 39, 41, 43, 45, 49-54, and 67-70,
or
e) the light chain variable region comprises a sequence at least about 90% identical
to any one of SEQ ID NO: 56, 58, 60, and 62.

### Claim 8 (depends on 1)

The antibody or fragment of claim 1, wherein:
a) the heavy chain variable region comprises a sequence at least about 90% identical to any one of SEQ ID NO: 2, 4, 6, and 8; and the light chain variable region comprises a sequence at least about 90% identical to any one of SEQ ID NO: 3, 5, 7, and 9,
b) the heavy chain variable region comprises a sequence at least about 90% identical to any one of SEQ ID NO: 10, 12, 14, and 16; and the light chain variable region comprises a sequence at least about 90% identical to any one of SEQ ID NO: 11, 13, 15, and 17,
c) the heavy chain variable region comprises a sequence at least about 90% identical to any one of SEQ ID NO: 18, 20, 22, 24, and 26-33; and the light chain variable region comprises a sequence at least about 90% identical to any one of SEQ ID NO: 19, 21, 23, 25, and 34-37,
d) the heavy chain variable region comprises a sequence at least about 90% identical to any one of SEQ ID NO: 38, 40, 42, 44, 46-48, and 63-66; and the light chain variable region comprises a sequence at least about 90% identical to any one of SEQ ID NO: 39, 41, 43, 45, 49-54, and 67-70, or
e) the heavy chain variable region comprises a sequence at least about 90% identical to any one of SEQ ID NO: 55, 57, 59, and 61; and the light chain variable region comprises a sequence at least about 90% identical to any one of SEQ. ID NO 56, 58, 60, and 62.

### Claim 9 (depends on 1)

The antibody or fragment of claim 1, wherein:
a) the heavy chain variable region comprises a sequence identical or comprising 1, 2, or 3 amino acid residue mutations relative to the three CDRs in any one of SEQ ID NO: 2, 4, 6, and 8;
b) the heavy chain variable region comprises a sequence identical or comprising 1, 2, or 3 amino acid residue mutations relative to the three CDRs in any one of SEQ ID NO: 10, 12, 14, and 16;
c) the heavy chain variable region comprises a sequence identical or comprising 1, 2, or 3 amino acid residue mutations relative to the three CDRs in any one of SEQ ID NO: 18, 20, 22, 24, and 26-33;
d) the heavy chain variable region comprises a sequence identical or comprising 1, 2, or 3 amino acid residue mutations relative to the three CDRs in any one of SEQ ID NO: 38, 40, 42, 44, 46-48, and 63-66; or
e) the heavy chain variable region comprises a sequence identical or comprising 1, 2, or 3 amino acid residue mutations relative to the three CDRs in any one of SEQ ID NO: 55, 57, 59, and 61.

### Claim 10 (depends on 1)

The antibody or fragment of claim 1, wherein:
a) the light chain variable region comprises a sequence identical or comprising 1, 2, or 3 amino acid residue mutations relative to the three CDRs in any one of SEQ ID NO: 3, 5, 7, and 9,
b) the light chain variable region comprises a sequence identical or comprising 1, 2, or 3 amino acid residue mutations relative to the three CDRs in any one of SEQ ID NO: 11, 13, 15, and 17,
c) the light chain variable region comprises a sequence identical or comprising 1, 2, or 3 amino acid residue mutations relative to the three CDRs in any one of SEQ ID NO: 19, 21, 23, 25, and 34-37,
d) the light chain variable region comprises a sequence identical or comprising 1, 2, or 3 amino acid residue mutations relative to the three CDRs in any one of SEQ ID NO: 39, 41, 43, 45, 49-54, and 67-70, or
e) the light chain variable region comprises a sequence identical or comprising 1, 2, or 3 amino acid residue mutations relative to the three CDRs in any one of SEQ ID NO: 56, 58, 60, and 62.

### Claim 11 (depends on 1)

The antibody or fragment of claim 1, wherein:
a) the heavy chain variable region comprises a sequence identical or comprising 1, 2, or 3 amino acid residue mutations relative to the three CDRs in any one of SEQ ID NO: 2, 4, 6, and 8; and/or the light chain variable region comprises a sequence identical or comprising 1, 2, or 3 amino acid residue mutations relative to the three CDRs in any one of SEQ ID NO: 3, 5, 7, and 9,
b) the heavy chain variable region comprises a sequence identical or comprising 1, 2, or 3 amino acid residue mutations relative to the three CDRs in any one of SEQ ID NO: 10, 12, 14, and 16; and/or the light chain variable region comprises a sequence identical or comprising 1, 2, or 3 amino acid residue mutations relative to the three CDRs in any one of SEQ ID NO: 11, 13, 15, and 17,
c) the heavy chain variable region comprises a sequence identical or comprising 1, 2, or 3 amino acid residue mutations relative to the three CDRs in any one of SEQ ID NO: 18, 20, 22, 24, and 26-33; and/or the light chain variable region comprises a sequence identical or comprising 1, 2, or 3 amino acid residue mutations relative to the three CDRs in any one of SEQ ID NO: 19, 21, 23, 25, and 34-37,
d) the heavy chain variable region comprises a sequence identical or comprising 1, 2, or 3 amino acid residue mutations relative to the three CDRs in any one of SEQ ID NO: 38, 40, 42, 44, 46-48, and 63-66; and/or the light chain variable region comprises a sequence identical or comprising 1, 2, or 3 amino acid residue mutations relative to the three CDRs in any one of SEQ ID NO: 39, 41, 43, 45, 49-54, and 67-70,
or
e) the heavy chain variable region comprises a sequence identical or comprising 1, 2, or 3 amino acid residue mutations relative to the three CDRs in any one of SEQ ID NO: 55, 57, 59, and 61; and/or the light chain variable region comprises a sequence identical or comprising 1, 2, or 3 amino acid residue mutations relative to the three CDRs in any one of SEQ ID NO: 56, 58, 60, and 62.

### Claim 12 (depends on 1)

The antibody or fragment of claim 1, wherein the antibody or fragment comprises any of the combinations of heavy chain and light chain variable regions in Table 2.

### Claim 13 (depends on 1)

The antibody or fragment of claim 1, wherein the antibody is capable of binding to CXCR3 with an affinity constant of at least about 108 M−1.

### Claim 14 (depends on 1)

The antibody or fragment of claim 1, wherein the antibody or fragment is capable of binding to both the A and B isoforms of CXCR3.

### Claim 15 (depends on 1)

The antibody or fragment of claim 1, wherein the antibody or fragment is capable of preferentially binding to the A-isoform of CXCR3.

### Claim 16 (depends on 1)

The antibody or fragment of claim 1, wherein the antibody or fragment is capable of neutralizing CXCR3 activity.

### Claim 17 (depends on 1)

An isolated nucleic acid encoding the amino acid sequence of the antibody or fragment of claim 1.

### Claim 18 (depends on 17)

A vector comprising the isolated nucleic acid of claim 17.

### Claim 19 (depends on 18)

A host cell comprising the vector of claim 18.

### Claim 20 (depends on 1, 19)

A method of producing the antibody or fragment of claim 1, comprising culturing the host cell of claim 19 in culture medium under conditions suitable to produce the antibody or fragment.

### Claim 21 (depends on 1, 17)

A kit comprising the antibody or fragment of claim 1 or the nucleic acid of claim 17 and instructions for using the antibody or fragment for research, diagnostic, or therapeutic purposes

### Claim 22 (depends on 1)

A method of preventing, treating or reducing the progression of new onset type 1 diabetes (T1D) comprising:
a) identifying a subject at risk for developing T1D or who has new onset T1D; and
b) administering an effective amount of the antibody or fragment of claim 1 to the subject, thereby prophylactically preventing the development of T1D, or treating or reducing the progression of new onset T1D.

### Claim 23 (depends on 22)

The method of claim 22, wherein the subject is a mammal.

### Claim 24 (depends on 22)

The method of claim 22, wherein the subject is human.

### Claim 25 (depends on 22)

The method of claim 22, wherein the subject has a basal serum C-peptide level of greater than or equal to about 0.2 nmol/L, and/or wherein the patient has a fasting integrated serum C-peptide level during C-peptide stimulation of between about 0.033 and 1.0 nmol/L×min.

### Claim 26 (depends on 22)

The method of claim 22, wherein the patient has a fasting blood glucose level of greater than about 120 mg/dL in the absence of exogenous insulin.

### Claim 27 (depends on 22)

The method of claim 22, wherein the antibody or fragment thereof is humanized.

### Claim 28 (depends on 22)

The method of claim 22, wherein the antibody or fragment thereof is administered at a dose of about 0.03-3.7 mg/kg/dose.

### Claim 29 (depends on 22)

The method of claim 22, wherein the antibody or fragment thereof is administered at least daily, weekly, biweekly, monthly; bimonthly, quarterly, or yearly.

### Claim 30 (depends on 22)

The method of claim 22, wherein the antibody or fragment thereof is administered at a total dose over all administrations of about 0.16-18 mg/kg.

### Claim 31 (depends on 22)

The method of claim 22, wherein the antibody or fragment thereof is administered intravenously, intraperitoneally, nasally, occularly, orally, parenterally, subcutaneously, or transdermally.

### Claim 32 (depends on 22)

The method of claim 22, wherein the antibody or fragment thereof is administered directly to the pancreas.

### Claim 33 (depends on 32)

The method of claim 32, wherein the antibody or fragment thereof is administered proximate to islet cells in the pancreas.

### Claim 34 (depends on 22)

The method of claim 22, wherein the method further comprises administering a β-cell stimulating agent, insulin, or an insulin-producing cell.

### Claim 35 (depends on 22)

The method of claim 22, wherein the method further comprises administering an immunosuppressant.

### Claim 36 (depends on 1)

A method of treating or reducing the progression of new onset type 1 diabetes (T1D) comprising:
a) identifying a human subject having new onset T1D and having a basal serum C-peptide level of greater than or equal to about 0.2 nmol/L, and/or having a fasting integrated serum C-peptide level during C-peptide stimulation of between about 0.033 and 1.0 nmol/L×min; and
b) administering about 0.03-3.7 mg/kg/dose of an antibody or fragment of claim 1, thereby treating or reducing the progression of new onset T1D.

### Claim 37 (depends on 1)

A CXCR3 neutralizing antibody or fragment thereof for preventing, treating or reducing the progression of new onset type 1 diabetes (T1D) in a subject, wherein the antibody or fragment thereof comprises the antibody or fragment of claim 1.

### Claim 38

An antibody or antigen binding fragment capable of binding to CXCR3, wherein the antibody or fragment comprises a heavy chain variable region (VH) and a light chain variable region (VL), and wherein:
a) the heavy chain variable region comprises a sequence at least about 90% identical to any one of SEQ ID NO: 2, 4, 6, and 8; and/or the light chain variable region comprises a sequence at least about 90% identical to any one of SEQ ID NO: 3, 5, 7, and 9,
b) the heavy chain variable region comprises a sequence at least about 90% identical to any one of SEQ ID NO: 10, 12, 14, and 16; and/or the light chain variable region comprises a sequence at least about 90% identical to any one of SEQ ID NO: 11, 13, 15, and 17,
c) the heavy chain variable region comprises a sequence at least about 90% identical to any one of SEQ ID NO: 18, 20, 22, 24, and 26-33; and/or the light chain variable region comprises a sequence at least about 90% identical to any one of SEQ ID NO: 19, 21, 23, 25, and 34-37,
d) the heavy chain variable region comprises a sequence at least about 90% identical to any one of SEQ ID NO: 38, 40, 42, 44, 46-48, and 63-66; and/or the light chain variable region comprises a sequence at least about 90% identical to any one of SEQ ID NO: 39, 41, 43, 45, 49-54, and 67-70, or
e) the heavy chain variable region comprises a sequence at least about 90% identical to any one of SEQ ID NO: 55, 57, 59, and 61; and/or the light chain variable region comprises a sequence at least about 90% identical to any one of SEQ ID NO: 56, 58, 60, and 62.

### Claim 39 (depends on 38)

The antibody or fragment of claim 38, wherein:
a) the heavy chain variable region comprises a sequence identical or comprising 1-10 amino acid residue mutations relative to any one of SEQ ID NO: 2, 4, 6, and 8; and/or the light chain variable region comprises a sequence identical or comprising 1-10 amino acid residue mutations relative to any one of SEQ ID NO: 3, 5, 7, and 9,
b) the heavy chain variable region comprises a sequence identical or comprising 1-10 amino acid residue mutations relative to any one of SEQ ID NO: 10, 12, 14, and 16; and/or the light chain variable region comprises a sequence identical or comprising 1-10 amino acid residue mutations relative to any one of SEQ ID NO: 11, 13, 15, and 17,
c) the heavy chain variable region comprises a sequence identical or comprising 1-10 amino acid residue mutations relative to any one of SEQ ID NO: 18, 20, 22, 24, and 26-33; and/or the light chain variable region comprises a sequence identical or comprising 1-10 amino acid residue mutations relative to any one of SEQ ID NO: 19, 21, 23, 25, and 34-37,
d) the heavy chain variable region comprises a sequence identical or comprising 1-10 amino acid residue mutations relative to any one of SEQ ID NO: 38, 40, 42, 44, 46-48, and 63-66; and/or the light chain variable region comprises a sequence identical or comprising 1-10 amino acid residue mutations relative to any one of SEQ ID NO: 39, 41, 43, 45, 49-54, and 67-70, or
e) the heavy chain variable region comprises a sequence identical or comprising 1-10 amino acid residue mutations relative to any one of SEQ ID NO: 55, 57, 59, and 61; and/or the light chain variable region comprises a sequence identical or comprising 1-10 amino acid residue mutations relative to any one of SEQ ID NO: 56, 58, 60, and 62.

### Claim 40 (depends on 38)

The antibody or fragment of claim 38, wherein:
a) the heavy chain variable region comprises three CDRs that are at least about 95% identical to the three CDRs from any one of SEQ ID NO: 2, 4, 6, and 8; and/or the light chain variable region comprises three CDRs that are at least about 95% identical to the three CDRs from any one of SEQ ID NO: 3, 5, 7, and 9,
b) the heavy chain variable region comprises three CDRs that are at least about 95% identical to the three CDRs from any one of SEQ ID NO: 10, 12, 14, and 16; and/or the light chain variable region comprises three CDRs that are at least about 95% identical to the three CDRs from any one of SEQ ID NO: 11, 13, 15, and 17,
c) the heavy chain variable region comprises three CDRs that are at least about 95% identical to the three CDRs from any one of SEQ ID NO: 18, 20, 22, 24, and 26-33; and/or the light chain variable region comprises three CDRs that are at least about 95% identical to the three CDRs from any one of SEQ ID NO: 19, 21, 23, 25, and 34-37,
d) the heavy chain variable region comprises three CDRs that are at least about 95% identical to the three CDRs from any one of SEQ ID NO: 38, 40, 42, 44, 46-48, and 63-66; and/or the light chain variable region comprises three CDRs that are at least about 95% identical to the three CDRs from any one of SEQ ID NO: 39, 41, 43, 45, 49-54, and 67-70, or
e) the heavy chain variable region comprises three CDRs that are at least about 95% identical to the three CDRs from any one of SEQ ID NO: 55, 57, 59, and 61; and/or the light chain variable region comprises three CDRs that are at least about 95% identical to the three CDRs from any one of SEQ ID NO: 56, 58, 60, and 62.

### Claim 41 (depends on 1)

A conjugate comprising the antibody or fragment of claim 1 and at least one additional agent.

### Claim 42 (depends on 41)

The conjugate of claim 41, wherein the additional agent is a therapeutic agent, a solubalizing agent, a stabilizing agent, an immunosuppressant, a receptor, or an antigen binding peptide.

### Claim 43 (depends on 1, 17)

A pharmaceutical composition comprising the antibody or fragment of claim 1, or the nucleic acid of claim 17, and a pharmaceutically acceptable carrier.

### Claim 44 (depends on 43)

The pharmaceutical composition of claim 43, wherein the composition further comprises at least one additional therapeutic agent.

### Claim 45 (depends on 44)

The pharmaceutical composition of claim 44, wherein the at least one additional therapeutic agent comprises an agent for treating a disease or disorder associated with CXCR3.

### Claim 46 (depends on 47)

The pharmaceutical composition of claim 47, wherein the at least one additional therapeutic agent comprises a n-cell stimulating agent, insulin, or an insulin-producing cell.

### Claim 47 (depends on 1)

A method of detecting the presence or concentration of CXCR3 in a test sample, comprising contacting the test sample with the antibody or fragment of claim 1 and a detectable label, wherein the presence or concentration of CXCR3 is directly or indirectly correlated with a signal generated by the detectable label.

### Claim 48 (depends on 47)

The method of claim 47, wherein the method is used to diagnose a condition associated with CXCR3.

### Claim 49 (depends on 48)

The method of claim 48, wherein the condition is T1D.
